Articles related to BREAST SURGERY

The video features an interview with Dr. Jason Mouabbi, a surgical oncologist, who discusses the management of invasive lobular carcinoma (ILC), a type of breast cancer that is less common than other types. He explains that ILC is more challenging to diagnose than other breast cancers because it does not form a lump, but rather spreads in a linear fashion throughout the breast tissue. Dr. Mouabbi highlights the importance of early detection and screening for ILC. He then discusses the treatment options for ILC, which may include surgery, radiation therapy, and hormone therapy. He emphasizes the need for personalized treatment plans for each patient based on their specific case and individual needs. Dr. Mouabbi also talks about the potential role of neoadjuvant therapy in improving outcomes for patients with ILC. Overall, the video provides valuable insights into the management of ILC and highlights the importance of early detection and personalized treatment plans.

The National Cancer Database analysis highlights the difficulty in identifying a single time point before which primary surgery should be completed in patients with breast cancer. There were two major findings: (1) 12% of patients who had surgery more than 8 weeks after diagnosis had significantly lower overall survival, and (2) patients with lower socioeconomic status had a longer time to surgery.

This six-chapter video series covers patient selection for neoadjuvant systemic treatment, adjuvant systemic treatment, neoadjuvant systemic treatment, post-neoadjuvant adjuvant treatment, survivorship and surveillance, and future directions.

Joyce A. O’Shaughnessy, MD provides updates on several key presentations from SABCS, touching on SERD therapy, ribociclib combinations, the datopotamab deruxtecan antibody-drug conjugate targeting overexpression of the calcium signal transducer TROP2, trastuzumab deruxtecan, and more. The MONALEESA phase 3 trial is looking at letrozole + ribociclib vs letrozole + placebo in postmenopausal women with ER+ HER2- advanced breast cancer. The trial arm outperformed the control arm with a median OS of 63.9 months vs 51.4 months respectively at a median follow up of just over 6.5 years. That median OS is the longest reported for any phase 3 trial in advanced breast cancer.